Allergy Therapeutics Archives

News and Trends 8 Dec 2022

Allergy Therapeutics moves ahead with peanut and grass pollen allergy trials

Allergy Therapeutics has announced the first subject has been dosed in the pivotal phase III G306 trial, to evaluate the efficacy and safety of Grass MATA MPL. Grass MATA MPL…

December 8, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 18 Mar 2019

Shares Drop 40% as Allergy Therapeutics Announces Failed Phase III Trial

Allergy Therapeutics has revealed that its immunotherapy for birch pollen allergy did not result in a significant symptom improvement when compared to a placebo. As a direct result of the…

March 18, 2019 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 May 2018

Positive House Dust Mite Immunotherapy Results for UK Biotech

British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy. It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for…

May 29, 2018 - 1 minutemin - By Helen Albert

News and Trends 23 May 2018

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained…

May 23, 2018 - 2 minutesmins - By Alexander Burik

News and Trends 18 Sep 2017

British Rapid Action Allergy Vaccine Gets Approval for Phase II Trial

Allergy Therapeutics' vaccine against hayfever has received approval to begin a trial to determine its optimal dose. Allergy Therapeutics will begin a Phase II trial of its PQ Grass vaccine…

September 18, 2017 - 2 minutesmins - By Alex Dale

News and Trends 14 Feb 2017

Suffering from House Dust Mite Allergy? A New Therapy is on its Way

Allergy Therapeutics, a UK-based biotech company, just announced the approval of its clinical trial application in Spain to advance its next-generation house dust mite allergy vaccine into phase I clinical…

February 14, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 10 Feb 2017

Germany gains Strength in Allergy Immunotherapeutics

Bencard Allergie is developing ultra-short course allergy immunotherapies, backed by a strong growth in its German market. Bencard Allergie is the German subsidiary of Allergy Therapeutics in the UK, which…

February 10, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

allergy therapeutics birch pollen rhinitis biotech uk

News and Trends 9 May 2016

UK Biopharma joins Allergy race with good Phase II results for Hayfever

Allergy Therapeutics has gotten positive results for its phase II trial for birch pollen allergy - another win for their Pollinex platform. Based near Brighton (UK), Allergy Therapeutics has around…

May 9, 2016 - 2 minutesmins - By Denise Neves Gameiro

Resources

Categories

The latest news on

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

The Biotech Perspective 2023

View all companies A-Z

Find new scientific partnerships. Create a free IN-PART account

Americas

Asia Pacific

Europe

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Company

Join Us

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering